AEs leading to dose discontinuations included thrombocytopenia (2.5%), tumor hemorrhage, seizure, dyspnea, laryngeal inflammation, nausea, stomatitis, bladder dilation, urinary retention, increased alanine aminotransferase, increased aspartate aminotransferase, decreased platelet count, and increased alkaline phosphatase (each 1.3%). Here, GPT is linked to Thrombocytopenia.